Paul Harden - Brentwood CA, US Terry Hermiston - Corte Madera CA, US Irene Kuhn - Richmond CA, US
International Classification:
C12N 15/63 A61K 35/00
US Classification:
4353201, 435 911, 435 914, 435 9142, 536 231
Abstract:
The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
Paul Harden - Brentwood CA, US Terry Hermiston - Corte Madera CA, US Irene Kuhn - Richmond CA, US
Assignee:
PsiOxus Therapeutics Limited - London
International Classification:
A61K 48/00 C12N 15/00
US Classification:
514 44, 4353201
Abstract:
The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
Paul HARDEN - Brentwood CA, US Terry HERMISTON - Corte Madera CA, US Irene KUHN - Richmond CA, US
Assignee:
PsiOxus Therapeutics Limited - London
International Classification:
C12N 7/01
US Classification:
4352351
Abstract:
The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
Paul Harden - Brentwood CA, US Terry Hermiston - Corte Madera CA, US Irene Kuhn - Richmond CA, US
International Classification:
C12N 7/00
US Classification:
424 932, 4352351, 435375
Abstract:
The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
Paul HARDEN - Brentwood CA, US Terry HERMISTON - Corte Madera CA, US Irene KUHN - Richmond CA, US
Assignee:
PSIOXUS THERAPEUTICS LIMITED - London
International Classification:
A61K 35/76
US Classification:
4352351
Abstract:
The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.
"Our original observation was very intriguing, that there was something that was produced by normal cells that was capable of killing cancer cells, so we decided to follow up," says Irene Kuhn of the Lawrence Berkeley National Laboratory in California, a member of the team that did the research in